Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
Alzheimer's disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role of caregivers. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-07-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.37023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857559283433472 |
|---|---|
| author | Hannah W. Haddad Garett W. Malone Nicholas J. Comardelle Arielle E. Degueure Salomon Poliwoda Rachel J. Kaye Kevin S. Murnane Adam M Kaye Alan D. Kaye |
| author_facet | Hannah W. Haddad Garett W. Malone Nicholas J. Comardelle Arielle E. Degueure Salomon Poliwoda Rachel J. Kaye Kevin S. Murnane Adam M Kaye Alan D. Kaye |
| author_sort | Hannah W. Haddad |
| collection | DOAJ |
| description | Alzheimer's disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role of caregivers. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays accounting for an estimated \$290 billion. Cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists have historically been the most widely used pharmacologic therapies for patients with AD; however, these drugs are not curative. The present investigation describes the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, Adulhelm, in the treatment of AD. Currently, Adulhelm is the only Food and Drug Administration (FDA) approved drug that acts to slow the progression of this disease. Adulhelm is an anti-amyloid drug that functions by selectively binding amyloid aggregates in both the oligomeric and fibrillar states. Studies show Adulhelm may help to restore neurological function in patients with AD by reducing beta-amyloid plaques and reestablishing neuronal calcium permeability. At present, there is concern the magnitude of this drug's benefit may only be statistically significant, although not clinically significant. Despite skepticism, Adulhelm has proven to significantly decrease amyloid in all cortical brain regions examined. With such high stakes and potential, further research into Adulhelm's clinical efficacy is warranted in the treatment of AD. |
| format | Article |
| id | doaj-art-441ead4fe8284740ae75b4bc58e66380 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-441ead4fe8284740ae75b4bc58e663802025-02-11T20:30:29ZengOpen Medical PublishingHealth Psychology Research2420-81242022-07-01102Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive reviewHannah W. HaddadGarett W. MaloneNicholas J. ComardelleArielle E. DegueureSalomon PoliwodaRachel J. KayeKevin S. MurnaneAdam M KayeAlan D. KayeAlzheimer's disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role of caregivers. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays accounting for an estimated \$290 billion. Cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists have historically been the most widely used pharmacologic therapies for patients with AD; however, these drugs are not curative. The present investigation describes the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, Adulhelm, in the treatment of AD. Currently, Adulhelm is the only Food and Drug Administration (FDA) approved drug that acts to slow the progression of this disease. Adulhelm is an anti-amyloid drug that functions by selectively binding amyloid aggregates in both the oligomeric and fibrillar states. Studies show Adulhelm may help to restore neurological function in patients with AD by reducing beta-amyloid plaques and reestablishing neuronal calcium permeability. At present, there is concern the magnitude of this drug's benefit may only be statistically significant, although not clinically significant. Despite skepticism, Adulhelm has proven to significantly decrease amyloid in all cortical brain regions examined. With such high stakes and potential, further research into Adulhelm's clinical efficacy is warranted in the treatment of AD.https://doi.org/10.52965/001c.37023 |
| spellingShingle | Hannah W. Haddad Garett W. Malone Nicholas J. Comardelle Arielle E. Degueure Salomon Poliwoda Rachel J. Kaye Kevin S. Murnane Adam M Kaye Alan D. Kaye Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review Health Psychology Research |
| title | Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review |
| title_full | Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review |
| title_fullStr | Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review |
| title_full_unstemmed | Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review |
| title_short | Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review |
| title_sort | aduhelm a novel anti amyloid monoclonal antibody for the treatment of alzheimer s disease a comprehensive review |
| url | https://doi.org/10.52965/001c.37023 |
| work_keys_str_mv | AT hannahwhaddad aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT garettwmalone aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT nicholasjcomardelle aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT arielleedegueure aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT salomonpoliwoda aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT racheljkaye aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT kevinsmurnane aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT adammkaye aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview AT alandkaye aduhelmanovelantiamyloidmonoclonalantibodyforthetreatmentofalzheimersdiseaseacomprehensivereview |